Optimizing aminoglycoside selection for KPC-producing <i>Klebsiella pneumoniae</i> with the aminoglycoside-modifying enzyme (AME) gene <i>aac(6’)-Ib</i>

Abstract

Gentamicin may be preferred over amikacin or tobramycin for treatment of KPC-Kp infections. However, gentamicin MICs are not a consistent predictor of its pharmacodynamic activity and unexpected treatment failures are possible.